Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has recently led a successful bid to establish a €52M international consortium to develop induced pluripotent stem (iPS) cell lines for drug discovery and safety assessment.

Dopamine neurons (in green) grown using stem cell technology
Dopamine neurons (in green) grown using stem cell technology

The StemBANCC bid, led by Dr Zam Cader was truly a team effort and involved researchers from across Oxford including the Nuffield Department of Clinical Neurosciences, Dunn School of Pathology, the MRC Functional Genetics Unit, the Departments of Chemistry, Psychiatry, Pharmacology, and Physiology Anatomy and Genetics, the Oxford Centre for Diabetes, Endocrinology and Metabolism and the Centre for Health, Law and Emerging Technologies.

The consortium also includes academic researchers and big pharma partners from across the UK and 10 other European countries. The project will build on Oxfords established strength in iPS cell technology to deliver a robust platform for research and to support drug discovery in the areas of Alzheimer’s, Parkinson’s, Autism, Schizophrenia, Bipolar, Migraine, Pain and Diabetes.

Similar stories

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

COVID-19 infection has greater risk than vaccines of causing very rare neurological events

Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between a core team of Professors Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Dr Mark Howe at Boston University and Professor Dinos Meletis at the Karolinska Institute, as well as collaborators Professor Yulong Li at Peking University and Dr Michael Lin at Stanford University.

New genetic diagnosis technology for eye disease receives major funding award

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

Royal Commission Industrial Fellowship for Andrei-Claudiu Roibu with F. Hoffmann-La Roche Ltd

Mapping brain network activity from structural connectivity using deep learning

Researchers awarded Wellcome Innovator Grant to investigate role of brainstem nucleus in human consciousness

Researchers at Oxford University have received a prestigious Wellcome Innovator Grant for investigating the role of the pedunculopontine nucleus (PPN) – a brainstem nucleus – in human consciousness.